UPIBI Research Highlights How Genetic Variation Affects Drug Response in Metabolic Disease

Dr. James Whitaker and collaborators at UPIBI have published findings demonstrating how genetic differences—specifically single-nucleotide polymorphisms (SNPs)—can impact individual responses to medications used to treat metabolic disorders. The research offers valuable insight into the genetic underpinnings of variable drug efficacy in patients with conditions like type 2 diabetes.

This study supports the advancement of precision medicine by helping tailor treatments to a patient’s genetic profile, potentially improving therapeutic outcomes and reducing adverse effects. The findings mark a step forward in developing more personalized approaches to managing common chronic diseases.